Nasdaq:US$15.16 (+0.08) | HKEX:HK$23.20 (-0.30) | AIM:£2.26 (+0.01)
Search
News & Press Releases
123
4
56789
found Documents: 426
Announcements & Press Releases, Group | 8 Apr 2021

HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Hong Kong, Shanghai & Florham Park, NJ — Thu
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Mar 2021

HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies
— HMPL-306 is the sixth innovative oncology drug candidate discovered in house by HUTCHMED to enter into global development —   Hong Kong, Shanghai & Florham Park, NJ — Monday, March 29, 2021: Hutchison China MediTech Limited (“HUT
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 26 Mar 2021

2020 Annual Report and Notice of Annual General Meeting
Hong Kong, Shanghai, & Florham Park, NJ: Friday, March 26, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that its 2020 Annual Report together with the Notice of Annual General Meeting and the Form of Pr
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 24 Mar 2021

HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million
– Allows focus on China and global clinical development and market launches of key Oncology/Immunology assets –   Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, March 24, 2021: Hutchison China MediTech Limited (“HUTCHME
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 24 Mar 2021

HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 24, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) has initiated a Phase Ib/II study of surufatinib in combination with BeiGene’s tislelizumab in patients w
Read More
Download Press Release (PDF)
Group | 4 Mar 2021

Chi-Med becomes HUTCHMED
Today, we begin consolidating the two corporate identities that we have used since our inception.  Hutchison China MediTech, or Chi-Med, has been used as our group identity, while Hutchison MediPharma has been the identity of our novel drug R&D
Read More
Announcements & Press Releases, Group | 4 Mar 2021

Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity
Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT  Hong Kong, Shanghai & Florham Park, NJ––Thursday, March 4, 2021:  Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM), a
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 Jan 2021

Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, January 14, 2021: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the final analysis of savolitinib in Phase Ib TATTON study Parts B and D will be presente
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 11 Jan 2021

Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases
Hong Kong, Shanghai, San Diego & Florham Park, NJ: Monday, January 11, 2021: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”) today announce a strategic partnership to further dev
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Coverage | 30 Dec 2020

Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors
– Sulanda® is Chi-Med’s first oncology drug brought to market without a partnership and the company’s second oncology drug approved in China – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression o
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Dec 2020

Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
– Company plans to complete rolling submission in the first half of 2021 – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acce
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group, Press Coverage | 22 Dec 2020

Chi-Med to Present at the 39th Annual JP Morgan Healthcare Conference
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, December 22, 2020:  Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 39th Annual JP Morgan Heal
Read More
Download Press Release (PDF)
Oncology / Immunology | 8 Dec 2020

Chi-Med Hosts Ground-breaking Ceremony for a Large-Scale Manufacturing Plant in Zhangjiang, Shanghai
Tuesday, December 8, 2020 Shanghai: Chi-Med (Nasdaq/AIM: HCM) today held a ground-breaking ceremony in Zhangjiang Hi-Tech Park, Shanghai, commencing construction of a large-scale manufacturing plant for innovative drugs. Representatives from the S
Read More
View Article (PDF)
Announcements & Press Releases, Group | 17 Nov 2020

Chi-Med Announces US$100 Million Equity Investment by CPP Investments
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Hong Kong, Shanghai, & Florham Park, NJ: Tuesday
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 5 Nov 2020

Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, November 5, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that initial analysis of the first in human HMPL-689 Phase I dose escalation study will be pre
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 30 Oct 2020

Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences
Hong Kong, Shanghai, & Florham Park, NJ: Friday, October 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief Executive Officer of Chi-Med, will present or participate in the
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 20 Sep 2020

Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology
  ― Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”) ―   ― SANET-p results complement previously presented positive Pha
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 Sep 2020

Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 17, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that its New Drug Application (“NDA”) for surufatinib for the treatment of patients with
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 4 Sep 2020

Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
Hong Kong, Shanghai, & Florham Park, NJ: Friday, September 4, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated FRESCO-2, a Phase III registration study of fruquintinib for the treatment of patients with metas
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 3 Sep 2020

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Intrahepatic Cholangiocarcinoma in China
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 3, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth fa
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 24 Aug 2020

Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020
Hong Kong, Shanghai, & Florham Park, NJ: Monday, August 24, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the studies of surufatinib and fruquintinib will be presented
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Aug 2020

Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA’s CHMP
Hong Kong, Shanghai, & Florham Park, NJ: Monday, August 10, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it received scientific advice from the European Medicines Agency's (“EMA”) Committee for
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 30 Jul 2020

Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs
– Strong global pipeline progress – three U.S. FDA1 Fast Track Designations; surufatinib U.S. NDA2 preparations underway; and initiation of global Phase III for fruquintinib –  – Two further NDAs submitted in China – savolitinib in
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 28 Jul 2020

Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, July 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Eli Lilly and Company (“Lilly”) today announce an amendment to the 2013 License and Collaboration Agreeme
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 28 Jul 2020

Chi-Med’s NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China
Hong Kong, Shanghai & Florham Park, NJ: Tuesday, July 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announced that the China National Medical Products Administration (“NMPA”) has granted Priority Review st
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 24 Jul 2020

Chi-Med Initiates a Phase I Trial of IDH1/2 Dual Inhibitor in Patients with Hematological Malignancies in China
  — HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med —   Hong Kong, Shanghai & Florham Park, NJ: Friday, July 24, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has in
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 26 Jun 2020

Chi-Med to Announce 2020 Half-Year Financial Results
London: Friday, June 26, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its interim results for the six months ended June 30, 2020 on Thursday, July 30, 2020 at 12:00 noon British Summer Time (BST) (7:00 p
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 25 Jun 2020

Chi-Med Announces US$100 Million Equity Investment by General Atlantic
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   – Strategic investment demonstrates General Atlant
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 18 Jun 2020

Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer
London: Thursday, June 18, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation for the development of fruquintinib, for th
Read More
Download Press Release (PDF)
Announcements & Press Releases, Other Ventures, Press Releases | 9 Jun 2020

Chi-Med Announces US$95 million Guangzhou Land Compensation Agreement
London: Tuesday, June 9, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), its 50:50 joint venture with Guangzhou Baiyu
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 4 Jun 2020

Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China Following a Planned Interim Data Review
London: Thursday, June 4, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the Independent Data Monitoring Committee (IDMC) of the FRUTIGA study of fruquintinib has completed a planned interim data review.
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 1 Jun 2020

Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA
London: Monday June 1, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it has held its pre-New Drug Application (“NDA”) meeting with the U.S. Food and Drug Administration (“FDA”) for surufatinib f
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 May 2020

Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
Press Release   — First NDA filing of savolitinib globally — —  Chi-Med seeking first-in-class Chinese marketing authorization for a selective MET inhibitor —   London: Friday, May 29, 2020: Hutchison China MediTech Limi
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 May 2020

Chi-Med to Discuss Select Global Clinical Trial Data Presented at ASCO20
Press Release   ― Savolitinib in MET exon 14 skipping NSCLC efficacy evaluable patients demonstrated 49.2% ORR, 93.4% DCR and 9.6 months DoR, including 36% patients with more aggressive disease subtype ― ― Savolitinib vs. sunitinib stu
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 26 May 2020

Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab
Press Release   – Collaboration to explore multiple solid tumor cancer indications – – Initial development focused on multi-cohort trials in the U.S., Europe, China and Australia –   LONDON, UK; CAMBRIDGE, Mass. and BEIJING
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 May 2020

Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program
London: Thursday, May 14, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of savolitinib, surufatinib, and fruquintinib will be presented at the upcoming AS
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 11 May 2020

Chi-Med to Attend Upcoming Investor Conferences
London: Monday, May 11, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Healt
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Coverage | 22 Apr 2020

Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings
London: Wednesday, April 22, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of surufatinib will be presented at the upcoming American Association for Cance
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 Apr 2020

Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors
London: Friday, April 17, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted two Fast Track Designations for the development of surufatinib, for
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 31 Mar 2020

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China
London: Tuesday, March 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth factor receptors (“FGFR”), in patients
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 25 Mar 2020

2019 Annual Report and Notice of Annual General Meeting
London: Wednesday, March 25, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/ AIM: HCM) today announces that its 2019 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy (“AGM Materials”) have bee
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 3 Mar 2020

Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs
Company to Host Annual Results Conference Call Today at 1:00 p.m. GMT / 8:00 a.m. EST / 9:00 p.m. HKT   London: Tuesday, March 3, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM), a commercial-stage biopharmaceutical comp
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 25 Feb 2020

Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions
London: Tuesday, February 25, 2020: Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that its final results for the year ended December 31, 2019 will be released on Tuesd
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Feb 2020

Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium
Press Release London: Monday, February 10, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of updated results from the Phase II CALYPSO study of the savolitinib / Imfinzi® (durvalumab) combi
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 6 Feb 2020

Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Thursday, February 6, 2020: Hutchiso
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 31 Jan 2020

Chi-Med to Announce 2019 Final Results
The announcement has been updated on February 25, please see the updated announcement here. London: Friday, January 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended Decem
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 23 Jan 2020

Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Thursday, January 23, 2020: Hutchiso
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 21 Jan 2020

Chi-Med Announces Proposed Public Offering of ADSs
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Tuesday, January 21, 2020: Hutchison
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 20 Jan 2020

Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early
London: Monday, January 20, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the Phase III pivotal study of surufatinib in advanced neuroendocrine
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 13 Jan 2020

Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors
Press Release London: Monday, January 13, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase II study in China of surufatinib in combination with Tuoyi (toripalimab) in patients with advanced solid tumors.
Read More
Download Press Release (PDF)
123
4
56789